FDA Approved: IBTROZI — Original Application (Nuvation Bio Inc.)

View source ↗

Summary

FDA approved IBTROZI (taletrectinib) in an original NDA for NTRK fusion‑positive solid tumors, providing a tumor‑agnostic treatment option.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Fusion-positive Solid Tumors

Drugs mentioned

• IBTROZI (taletrectinib)

Snippet

ORIG AP for IBTROZI (TALETRECTINIB)